Jennifer H. Foster, MD, MPH | Texas ...

Dr. Jennifer Foster, MD

Claim this profile

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Expert in Neuroblastoma
Expert in Cancer
34 reported clinical trials
53 drugs studied

Area of expertise

1Neuroblastoma
Global Leader
Jennifer Foster, MD has run 22 trials for Neuroblastoma. Some of their research focus areas include:
Stage IV
MYC positive
Stage I
2Cancer
Global Leader
Jennifer Foster, MD has run 22 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage I
Stage II

Affiliated Hospitals

Image of trial facility.
Baylor College Of Medicine/Dan L Duncan Comprehensive Cancer Center
Image of trial facility.
Texas Children's Hospital

Clinical Trials Jennifer Foster, MD is currently running

Image of trial facility.

CBL0137

for Cancer

This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.
Recruiting1 award Phase 1 & 213 criteria
Image of trial facility.

Dinutuximab + Chemotherapy

for High-Risk Neuroblastoma

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting2 awards Phase 37 criteria

More about Jennifer Foster, MD

Clinical Trial Related2 years of experience running clinical trials · Led 34 trials as a Principal Investigator · 8 Active Clinical Trials
Treatments Jennifer Foster, MD has experience with
  • Cyclophosphamide
  • Cytology Specimen Collection Procedure
  • Laboratory Biomarker Analysis
  • Larotrectinib
  • Palbociclib
  • Erdafitinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Jennifer Foster, MD specialize in?
Is Jennifer Foster, MD currently recruiting for clinical trials?
Are there any treatments that Jennifer Foster, MD has studied deeply?
What is the best way to schedule an appointment with Jennifer Foster, MD?
What is the office address of Jennifer Foster, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security